Related Experiment Videos
Escitalopram H Lundbeck
1Ralph H Johnson VA Medical Center, MUSC/Clinical Trials Network, Charleston, SC 29401-5799, USA. mcraeal@musc.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|September 5, 2002
Summary
Escitalopram, the (S)-enantiomer of citalopram, has gained regulatory approvals for depression treatment across Europe and other regions. Despite some delays, the drug
Area of Science:
- Pharmacology and Therapeutics
- Drug Development and Regulatory Affairs
Background:
- Escitalopram is the therapeutically active (S)-enantiomer of citalopram, developed as an improved treatment for depression.
- The drug's development and launch represent advancements in selective serotonin reuptake inhibitor (SSRI) therapy.
Purpose of the Study:
- To document the regulatory progress and market launch of escitalopram in various international markets.
- To track the timeline of approvals and identify any challenges encountered during the global rollout.
Main Methods:
- Review of regulatory submissions and approval dates across multiple countries.
- Monitoring of market launch activities and strategic partnerships.
- Analysis of regulatory timelines and reasons for withdrawal or delays in specific markets.
Main Results:
- Received approval for depression and panic disorder treatment in Sweden (December 2001) and Switzerland (January 2002).
- Secured approvals via the European Mutual Recognition Procedure in multiple EU countries by May 2002, with launches commencing post-negotiations.
- Experienced delays and withdrawal of applications in Portugal, Greece, Italy, Spain, Finland, and Germany, while awaiting FDA approval in the US.
Conclusions:
- Escitalopram demonstrated significant progress in global regulatory approvals for depression treatment.
- The drug's market entry involved complex negotiations and varied timelines across different regions, highlighting the challenges in international drug commercialization.